menu
    • menu

    Company profile for Oculis

    NEW Drugs in Dev: 4
    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    As a CDMO, Mikart offers integrated CDMO services for Solid Dose & Non-sterile Liquid formulations.

    Virtual Booth

    Contact Supplier

    Trusted Global CDMO Partner Delivering End-to-End Pharma Manufacturing & Development Solutions.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    REF. STANDARDS & IMPURITIES

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Oculis is a clinical stage biopharmaceutical company whose mission is to develop novel topical treatments (eye drops) for ophthalmic diseases for both back- and front-of-the-eye in order to improve the sight and the lives of patients worldwide.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OculisSwitzerland Flag
    Country
    Country
    Switzerland
    Address
    Address
    EPFL Innovation Park Building C 1015 Lausanne
    Telephone
    Telephone
    +41 21 711 3970
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://oculis.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    RDD

    RDD

    Not Confirmed

    envelop Contact Supplier

    RDD

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Oculis Reports Q1 2026 Results, Updates Company Outlook
    Oculis Reports Q1 2026 Results, Updates Company Outlook

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3292341/0/en/oculis-reports-q1-2026-financial-results-and-provides-company-update.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Oculis To Present At ARVO Annual Meeting
    Oculis To Present At ARVO Annual Meeting

    01 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7258552

    FIRSTWORD PHARMA
    01 May 2026
    Share Share
    Oculis Publishes Invitation To The Annual General Meeting
    Oculis Publishes Invitation To The Annual General Meeting

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278405/0/en/oculis-publishes-invitation-to-the-annual-general-meeting.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share
    Oculis Discloses Executive Transaction Notifications
    Oculis Discloses Executive Transaction Notifications

    08 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/08/3270493/0/en/Oculis-Publishes-Notifications-of-Transactions-by-Persons-Discharging-Managerial-Responsibilities.html

    GLOBENEWSWIRE
    08 Apr 2026
    Share Share
    Oculis To Participate In Upcoming Investor Conferences
    Oculis To Participate In Upcoming Investor Conferences

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3268862/0/en/Oculis-to-Participate-in-Upcoming-Investor-Conferences.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    Oculis Gets EMA PRIME for Privosegtor in Optic Neuritis
    Oculis Gets EMA PRIME for Privosegtor in Optic Neuritis

    31 Mar 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/03/31/3265214/0/en/Oculis-Announces-European-Medicines-Agency-PRIME-Designation-for-Privosegtor-Advancing-a-Potential-First-in-Class-Neuroprotective-Candidate-for-Optic-Neuritis.html

    GLOBENEWSWIRE
    31 Mar 2026
    Share Share

    REF. STANDARDS & IMPURITIES

    Upload your portfolio for free, ask us

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search